Loading..

BioNTech SE (BNTX) Q2 2021 Report Analysis


Filing Date

2021-08-09

Grade by Sector

53 / 100

Rating

Country

Germany

Exchange

NasdaqGS

Website

www.biontech.de

Market Cap

$108.0B

Sector

Health Care

Industry

Biotechnology

Rating

Grade by Sector

Filing Date

Market Cap

Country

Exchange

Sector

Industry

53 / 100

2021-08-09

$108.0B

Germany

NasdaqGS

Health Care

Biotechnology

Company Highlights


Parameter Value Change Score
Assets 9,148.8 118% 37
Capital Expenditure -89.79 -13% 57
Cash & Equivalents 914.1 3% 74
Equity 5,482.8 118% 69
Liabilities 3,666.0 118% 37
EBITDA 5,582.64 320% 64
Total Revenues 7,769.82 210% 41
Parameter Value Change Score
Free Cashflow -1.95 -25% 49
Cashflow 341.06 -22% 53
Asset Turnover 1.54 51% 74
Price to Book 8.41 -6% 77
Return on Equity 133.85 66% 75

* All values are TTM

Report Summary

The following analysis of BioNTech SE's expected performance over the upcoming quarter is based on a systematic deep dive into their income statement, balance sheet, & statement of cash flows. Moreover, a number of critical general factors and ratios are also utilized and included. First, assessing the balance sheet parameters did not keep up with market benchmarks. Next, the income statement performance metrics stayed at par with their benchmark in the above time frame. Moreover, cash flow parameters underperformed their benchmark. Last, the most impactful financial ratios suggest that in the coming months BioNTech SE's growth will just keep up with their benchmark. With all factors considered, our evaluation of BioNTech SE gave a total score of 53.

  •  BNTX
  •  Industry average

Balance Sheet Analysis

Auditing the results from the balance sheet shone a spotlight on certain key numbers that provide meaningful signals in the near term. Its important to underline the fact that balance sheet factors affect roughly up to 46.5% of the likelihood that the company will beat its benchmark performance throughout the upcoming quarter. In particular, diving deeper into BioNTech SE's debt service capabilities reveals satisfactory momentum concerning cash and cash equivalents. Statistically, the debt service capabilities factors are responsible for up to 2.9% of the company's likelihood to beat its benchmark. Next, the company's assets indicates lackluster momentum with connection to assets changes. The strength of a company's assets contribute up to 18.8% of the probability that the company will beat its benchmark. Third, their debt structure indicates weak sentiment concerning liabilities movement. In general, the debt structure factors influence up to 18.8% of the company's likelihood to over-perform. Moreover, their found slightly above average execution related to shareholders' equity and intangible assets adjustments. Intangible assets and technical changes influence roughly 6.0% of a company's probability to over-perform throughout the upcoming quarter. With all factors considered, BioNTech SE's balance sheet produced a total score of 54.

  •  BNTX
  •  Industry average
Parameter Value Change Score
Assets 9,148.8 118% 37
Capital Expenditure -89.79 -13% 57
Cash & Equivalents 914.1 3% 74
Equity 5,482.8 118% 69
Liabilities 3,666.0 118% 37
All values are TTM

Income Statement Analysis

Examination of the changes in their income statement shone a spotlight on a number of results that often have the most significant effect on company performance for the next quarter. First, analysis of BioNTech SE's net income indicates unexceptional results going into earnings movement. Typically, the company's net income influences 5.9% of the chances of the company to over-perform. Next, BioNTech SE's cost of sales forecasts average momentum in terms of capital expenditure growth. Generally, a Company's cost of sales can be responsible for up to 3.7% of a company's probability to over-perform its benchmark. Looking at BioNTech SE's revenue found sub-par results with connection to revenue momentum. Revenue momentum will impact around 2.2% of the company's likelihood to beat the market in the upcoming quarter. Bottom line, our evaluation of the company's income statement generated a score of 59.

  •  BNTX
  •  Industry average
Parameter Value Change Score
EBITDA 5,582.64 320% 64
Total Revenues 7,769.82 210% 41
All values are TTM

Cash Flow Analysis

Looking closer at changes reported in the companys cash flow focused our attention on several specific metrics that typically have the greatest effect on company performance in the coming months. First, assessing the companys flow of cash coming from operations, finance, and investments conveys middle of the road execution with connection to cash flow momentum. Generally, the flow of cash coming from operations, finance, and investments factors can affect up to 0.2% of the probability that the company will beat its benchmark performance. Particularly, their net cash flow indicates unremarkable performance related to free cash flow growth. Historically, these factors influence around 7.4% of the probability that a company will over-perform its benchmark in the course of the coming quarters. Our evaluation of the companys cash flow deserved a total score of 52.

  •  BNTX
  •  Industry average
Parameter Value Change Score
Free Cashflow -1.95 -25% 49
Cashflow 341.06 -22% 53
All values are TTM

General & Ratios Analysis

Our holistic analysis of these key factors in the reports gives us a panoramic view of their likelihood to over-perform for the upcoming quarter. Taking in consideration BioNTech SE's results connected to general factors forecasts below average execution related to macroeconomic environment. Moreover, our assessment of the company's health and sustainability implies positive momentum concerning book value momentum. Statistically, these factors influence up to 18.5% of the company's likelihood to beat the market. Reviewing a drill down into the company's capital efficiency signals positive overperformance with respect to assets factors momentum. Historically, the capital efficiency factors will contribute up to 13.5% of the likelihood that the company will beat its benchmark performance throughout the coming months. In particular, our analysis of investors' interest signals satisfactory execution going into return factors momentum. Historically, these factors impact up to 2.0% of the probability that the company will beat its benchmark performance for the current market. Last, looking closer at their capital efficiency shows positive overperformance with respect to assets factors momentum. Typically, the capital efficiency factors will impact around 13.5% of the probability that a company will beat the market during the next quarter. With all factors taken together, our cumulative ranking of their general factors and ratios produced the total score of 76.

  •  BNTX
  •  Industry average
Parameter Value Change Score
Asset Turnover 1.54 51% 74
Price to Book 8.41 -6% 77
Return on Equity 133.85 66% 75
All values are TTM

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.